Publication

Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer

Related publications (37)

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Melanoma causes the vast majority of skin cancer deaths, and there is currently no conventional treatment available that is able to cure metastatic melanoma patients. However, a novel treatment modality has recently emerged: cancer immunotherapy. Cancer im ...

EPFL2016

Fibronectin EDA and CpG synergize to enhance antigen-specific Th1 and cytotoxic responses

Eleonora Simeoni, Jeffrey Alan Hubbell, Melody Swartz, Alexandre de Titta, Alizée Jéléna Grimm, Ziad Julier

Subunit vaccines, employing purified protein antigens rather than intact pathogens, require the addition of adjuvants for enhanced immunogenicity with a correct balance between strong activation of the immune system and low toxicity. Here we show that the ...

Elsevier Sci Ltd2016

Immunotherapy has great potential to treat cancer and prevent future relapse by activating the immune system to recognize and kill cancer cells. A variety of strategies are continuing to evolve in the laboratory and in the clinic, including therapeutic non ...

Natl Acad Sciences2015

Emerging roles of lymphatic endothelium in regulating adaptive immunity

Melody Swartz, Catherine Mary Card

Emerging research on the roles of stromal cells in modulating adaptive immune responses has included a new focus on lymphatic endothelial cells (LECs). LECs are presumably the first cells that come into direct contact with peripheral antigens, cytokines, d ...

American Society for Clinical Investigation2014

The immunosuppressive tumor microenvironment represents a major hurdle to cancer therapy. We developed a gene transfer strategy into hematopoietic stem cells (HSCs) to target transgene expression to tumor-infiltrating monocytes/macrophages. Using a combina ...

2014

Targeting and Modulating Tumor-Associated Sites with Novel Nanoparticle-Based Immunotherapies

Laura Jeanbart

Cancer is a global disease and a leading cause of death worldwide. While surgery, radiotherapy and chemotherapy comprise the classical tools to eradicate tumors, they do not cure cancer, cannot prevent metastases, lead to side effects, and most importantly ...

EPFL2013

Tunable T cell immunity towards a protein antigen using polymersomes vs. solid-core nanoparticles

Jeffrey Alan Hubbell, Melody Swartz, Armando Stano, Karen Dane

Using poly(propylene sulfide) (PPS) and poly(ethylene glycol) (PEG) as components of a nanocarrier platform, we sought to compare immune responses induced by PPS-bl-PEG polymersomes (PSs; watery-core structures, with antigen incorporated within the PSs) an ...

Elsevier Sci Ltd2013

Synthesis and characterization of a new class of anti-angiogenic agent based on ruthenium clusters

Paul Joseph Dyson, Hubert van den Bergh, Patrycja Nowak-Sliwinska, Alexey Nazarov, Olivier Pierre Zava, Michael Groessl, Mathurin Baquié

New triruthenium-carbonyl clusters derivatized with glucose-modified bicyclophosphite ligands have been synthesized. These compounds were found to have cytostatic and cytotoxic activity and depending on the number of bicyclophosphite ligands, and could be ...

2013

Lymphocytes are a key component of the immune system and their differentiation and function are directly influenced by cancer. We examined peripheral blood lymphocyte (PBL) gene expression as a biomarker of illness and treatment effect using the Affymetrix ...

Public Library of Science2012

Improving Immunogenicity of Subunit Vaccines Using Nanocarrier Systems

Armando Stano

New generation vaccines, which are subunit vaccines, have considerably improved safety profiles, but are often poorly immunogenic, especially when administered through mucosal routes. Also, the diversity of the mechanisms of action of infectious pathogens ...

EPFL2012